BACKGROUND: Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years). METHODS: HCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays. RESULTS: HCV-specific T cell proliferation and IFN-gamma production were more common in nonviremic EIA-positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003). They were also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P= .04) and 0 of 24 nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P= .0115) than those without nAbs, but these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses. CONCLUSION: The reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
BACKGROUND: Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years). METHODS:HCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays. RESULTS:HCV-specific T cell proliferation and IFN-gamma production were more common in nonviremic EIA-positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003). They were also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P= .04) and 0 of 24 nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P= .0115) than those without nAbs, but these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses. CONCLUSION: The reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
Authors: S L Rowland-Jones; T Dong; K R Fowke; J Kimani; P Krausa; H Newell; T Blanchard; K Ariyoshi; J Oyugi; E Ngugi; J Bwayo; K S MacDonald; A J McMichael; F A Plummer Journal: J Clin Invest Date: 1998-11-01 Impact factor: 14.808
Authors: Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: David E Kaplan; Kazushi Sugimoto; Kimberly Newton; Mary E Valiga; Fusao Ikeda; Ayse Aytaman; Frederick A Nunes; Michael R Lucey; Barbara A Vance; Robert H Vonderheide; K Rajender Reddy; Jane A McKeating; Kyong-Mi Chang Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Thomas von Hahn; Joo Chun Yoon; Harvey Alter; Charles M Rice; Barbara Rehermann; Peter Balfe; Jane A McKeating Journal: Gastroenterology Date: 2006-12-03 Impact factor: 22.682
Authors: F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker Journal: J Exp Med Date: 2000-05-01 Impact factor: 14.307
Authors: Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert Journal: Proc Natl Acad Sci U S A Date: 2007-03-28 Impact factor: 11.205
Authors: Leslie H Tobler; Shrein H Bahrami; Zhanna Kaidarova; Lubov Pitina; Valarie K Winkelman; Sandra K Vanderpool; Anne M Guiltinan; Stewart Cooper; Michael P Busch; Edward L Murphy Journal: Transfusion Date: 2010-03-25 Impact factor: 3.157
Authors: J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench Journal: J Viral Hepat Date: 2010-07-05 Impact factor: 3.728
Authors: Theo Heller; Jens Martin Werner; Fareed Rahman; Eishiro Mizukoshi; Yuji Sobao; Ann Marie Gordon; Arlene Sheets; Averell H Sherker; Ellen Kessler; Kathleen S Bean; Steven K Herrine; M'lou Stevens; James Schmitt; Barbara Rehermann Journal: J Infect Dis Date: 2013-06-24 Impact factor: 5.226
Authors: Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga Journal: World J Gastroenterol Date: 2012-06-21 Impact factor: 5.742
Authors: Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp Journal: J Infect Dis Date: 2011-03-15 Impact factor: 5.226
Authors: Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott Journal: Mol Diagn Ther Date: 2009 Impact factor: 4.074